Kiniksa Pharmaceuticals International, plc Kiniksa Pharmaceuticals International, plc

Kiniksa Pharmaceuticals International, plc

KNSA

Clasificación en acciones #2875
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Precio por acción
$83.13
Última sincronización: 2026-10-20
Capitalización bursátil
$6.49B
Cambio (1 día)
4.59%
Cambio (1 año)
113.97%
País
GB
Comercio Kiniksa Pharmaceuticals International, plc (KNSA)

Categoría

Healthcare
Historial de desdoblamientos de acciones de Kiniksa Pharmaceuticals International, plc (KNSA)
La acción Kiniksa Pharmaceuticals International, plc (símbolo: KNSA) tuvo un total de 0 desdoblamientos.
El desdoblamiento más reciente ocurrió el Oct 21, 2026.
Una acción KNSA comprada antes de Oct 21, 2026 equivaldría hoy a 0 acciones KNSA.
Lista de desdoblamientos de acciones
Año Desdoblamiento Multiplicador Multiplicador acumulado
Not enough data for the provided dates.
Desdoblamientos de acciones de empresas similares o competidoras
Empresa Número de desdoblamientos de acciones Multiplicador acumulado País
0 -
US
0 -
SE
0 -
FR
0 -
IT
0 -
US